GU Cancers 2019 | Darolutamide for nmCRPC: results of the ARAMIS trial

Iris Kuss

Iris Kuss, MD, of Bayer HealthCare, Leverkusen, Germany, provides an overview of the ARAMIS study (NCT02200614), which tested the safety and efficacy of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC). Dr Kuss highlights the promising secondary and patient-relevant endpoint data of darolutamide, as well as the drug’s promising safety profile. This video was filmed at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video